Learn about our expanded patient care options for your health care needs.
General Information | Self-Checker | Donate and Lend Support | Staff Appreciation | Get Email Alerts
Enter the last name, specialty or keyword for your search below.
The Clinical Laboratory and Biomarkers Cores will coordinate access to laboratory expertise, testing, training, specimen repositories and Good Clinical Laboratory Practices (GCLP). The goals of this core are to assure that all JHU HIV investigators have access to and utilize appropriate, validated and, where applicable, certified laboratory assays. The core will also maintain a biomarker specimen repository for storage cataloguing and utilization of biological specimens.
Research in the Craig W. Hendrix Lab concentrates on the chemoprevention of HIV infection, clinical pharmacology of antiviral drugs, drug interactions, and oral, topical and injectable HIV microbicide development. Our lab conducts small, intensive sampling studies of PK and PD of drugs for HIV prevention with a focus on developing methods to better understand HIV and drug distribution in the male genital tract, female genital tract and lower gastrointestinal tract. We also support numerous HIV pre-exposure prophylaxis development studies from phase I to phase III, largely as leader of the Pharmacology Core Laboratory of both the Microbicide Trial Network and HIV Prevention Trials Network.
The David Celentano Lab studies behavioral and social epidemiology by integrating behavioral science theory and research with epidemiology methods. Our team directs epidemiological investigations and stages preventive interventions targeting HIV/AIDS and other sexually transmitted infections.
The David Graham Lab studies the consequences of HIV interactions with the immune system, the resulting pathogenesis and how to sabotage these interactions. We apply advanced technologies like mass spectrometry to dissect processes at the molecular level. We are also actively involved in cardiovascular research and studies the ways proteins are organized into functional units in different cell types of the heart.
Major projects in our lab are organized into three major areas: (1) H/SIV pathogenesis and neuropathogenesis, (2) Cardiovascular disease, and (3) High technology development
The David Thomas Lab oversees clinical research projects that aim to understand the natural history and pathogenesis of hepatitis C virus infection. A special area of clinical and research focus is liver disease in HIV-infected people.
Research in the Erica Johnson Lab investigates infection control in military deployment environments as well as infections that are associated with combat trauma. We explore topics such as HIV outcomes, gender-based health issues and disparities in care.
The Ernesto Freire Lab studies the use of novel drugs to treat disease. Our research has resulted in the development of a thermodynamic platform for drug discovery and optimization. Our aim is to achieve high binding affinity and selectivity as well as appropriate pharmacokinetics with the platform. We are currently focusing on drug targets such as HIV/-1 protease inhibitors (HIV/AIDS), plasmepsin inhibitors (malaria), HCV protease inhibitors (hepatitis C), coronavirus 3CL-pro protease inhibitors (SARS and other viral infections), HIV-1 gp120 inhibitors (HIV/AIDS), chymase inhibitors (cardiovascular disease) and beta lactamase inhibitors (antibiotic resistance).
The Gail Berkenblit Lab focuses on HIV testing. We are particularly interested in the training of residents as it relates to HIV outpatient care, and the development and assessment of online curriculum.
Our research focuses at the nexus of HIV and alcohol and other substance use. We examine epidemiological aspects of HIV and alcohol use/other drug use among persons with HIV (PWH), and work on the adaptation and testing of person and computer-delivered interventions for unhealthy alcohol use, particularly among women.
Research in the Gregory Kirk Lab examines the natural history of viral infections — particularly HIV and hepatitis viruses — in the U.S. and globally. As part of the ALIVE (AIDS Linked to the Intravenous Experience) study, our research looks at a range of pathogenetic, clinical behavioral issues, with a special focus on non-AIDS-related outcomes of HIV, including cancer and liver and lung diseases. We use imaging and clinical, genetic, epigenetic and proteomic methods to identify and learn more about people at greatest risk for clinically relevant outcomes from HIV, hepatitis B and hepatitis C infections. Our long-term goal is to translate our findings into targeted interventions that help reduce the disease burden of these infections.
Language Assistance Available:
© The Johns Hopkins University, The Johns Hopkins Hospital, and Johns Hopkins Health System. All rights reserved.
